Back to Search
Start Over
TT52CAR19: Phase 1 Trial of CRISPR/Cas9 Edited Allogeneic CAR19 T Cells for Paediatric Relapsed/Refractory B-ALL
- Source :
- Blood; November 2021, Vol. 138 Issue: Supplement 1 p4838-4838, 1p
- Publication Year :
- 2021
-
Abstract
- Qasim: Autolus: Current equity holder in publicly-traded company; Novartis: Honoraria; Servier: Research Funding; Tessa: Membership on an entity's Board of Directors or advisory committees.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 138
- Issue :
- Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs58316977
- Full Text :
- https://doi.org/10.1182/blood-2021-152426